期刊文献+

氨磷汀的细胞保护作用对肿瘤化疗病人生活质量的改善 被引量:5

Cytoprotective effects of amifostine during chemotherapy in the treatment of tumors
下载PDF
导出
摘要 目的探讨氨磷汀在肿瘤化疗中的细胞保护作用,减轻化疗副反应,从而改善病人的生活质量.方法对21例既往化疗后出现Ⅰ°~Ⅳ°血液学毒性及出现肾脏、肝脏毒性的患者化疗前应用氨磷汀600mg/m2,化疗前30min使用,静滴15min.结果病人用氨磷汀和不用氨磷汀的血液学毒性、PS评分及肾毒性的差异有显著性(P<0.05).结论氨磷汀在化疗前应用可以有效地保护正常组织免受细胞毒药物的损伤,进而改善化疗病人的生活质量,延长生存期. Objective To study the cytoprotective effect of amifostin On patients receiving chemotherapy. Methods Amifostin 600mg/m^2 iv 15min, 30min before chemotherapy, were given to patients having Ⅰ°-Ⅳ° blood toxicity, nephrotoxicitymhepatictoxicity in the past chemotherapy. Results Blood toxicity, PS score and nephroxicity were different significantly in the group receiving amifostin from the control group. Conclusion Amifostin can protect normal ceUs from the damage of cytotoxicitic agents effectively, also can improve the QOL of patients and prolong the survival.
出处 《哈尔滨医科大学学报》 CAS 北大核心 2005年第5期441-442,共2页 Journal of Harbin Medical University
关键词 氨磷汀 肿瘤化疗 生活质量 amifostin chemotherapy quality of life
  • 相关文献

参考文献6

  • 1Schuchter LM,Luginbuhl WE,Meropol NJ.The current status of toxicity protectants in cancer therapy[J].Semin Oncol,1992,19(6):742-751.
  • 2周际昌.实用肿瘤内科学[M].北京,人民卫生出版社,2000.353-362.
  • 3高红军,胡小电,杨武威,叶新红,王洪敏,翟红岩.顺铂为主联合化疗中氨磷汀对肾脏的保护作用[J].中国新医药,2004,3(4):20-22. 被引量:7
  • 4Illiano A,Barletta E,De Marino V,et al.New triplet che motherapy combination with carboplatin,paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer:a phase Ⅱ study[J].Anticancer Res,2000,20(5c):3999-4003.
  • 5申戈,鲍云华.防治癌症病人化疗毒性的临床及临床前研究[J].国外医学(药学分册),1999,26(6):325-329. 被引量:13
  • 6Wadler S,Haynes H,Beitler JJ,et al.Management of hypocalcemic effects of WR2721 administered on a daily times five schedule with cisplatin and radiation therapy.The New York Gynecologic Oncology Group[J].J Clin Oncol,1993,11(8):1517-1522.

二级参考文献1

共引文献46

同被引文献15

  • 1毛建芬.化疗前使用阿米福汀的观察与护理[J].护理与康复,2007,6(1):61-62. 被引量:7
  • 2Kouvaris J R, Kouloulias V E, Vlahos L J. Amifostine:The First Selective-Target and Broad-Spectrum Radioprotector[J]. The Oncologist, 2007, 12(6):738-747.
  • 3Rades D, Fehlauer F, Bajrovic A, et al. Serious Adverse Effects of Amifostine during Radiotherapy in Head and Neck Cancer Patients[J].Radiother Oncol,2004,70(3):261-264.
  • 4Koukourakis M I, Kyrias G, Kakolyris S, et al. Subcutaneous Administration of Amifostine during Fractionated Radiotherapy:A Randomized Phase Ⅱ Study[ J ]. J Clin Oncol,2000,18 (11):2226-2233.
  • 5Koukourakis M I, Simopoulos C, Minopoulos G,et al. Amifostine before Chemotherapy:Improved Tolerance Profile of the Subcutaneous over the Intravenous Route[ J ]. Clin Cancer Res,2003,9(9):3288-3293.
  • 6Bonner H S, Shaw L M. New Dosing Regimens for Amifostine: A Pilot Study to Compare the Relative Bioavailability of Oral and Subcutaneous Administration with Intravenous Infusion[ J ]. J Clin Pharmacol,2002,42(2): 166-174.
  • 7Illiano A,Barletta E,De Marino Y,et al.New triplet the chmotherapy combination with carboplation with paclitaxel and gemcitabine plus amifostine support in advanced non small cell lung cancer:a phase H study[J].Anticancer Res,2000,20(50c):3999 ~ 4003.
  • 8Shuchter LM.Guidelines for the administration of amifostine[J].Semin Oncol,1996,23 (4):40 ~ 43.
  • 9Chvertzoff G,Bonnotte B,Chanffert B.Anticancer chemotherapy prevention of toxicity[J].Press Med,1998,27(39):2106 ~2112.
  • 10刘文瑞,李俊.氨磷汀联合化疗治疗恶性肿瘤800例临床分析[J].山西职工医学院学报,2010,20(2):36-37. 被引量:1

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部